US Stock IR Daily – April 28, 2026 (9 reports)

• The Coca-Cola Company (KO) filed a Form 8-K with the U.S. Securities and Exchange Commission on April 28, 2026.
• The 8-K filing references a press release issued on the same date, reporting the company’s financial results for the first quarter of 2026.
• The press release, identified as Exhibit 99.1, reports The Coca-Cola Company’s financial results for the first quarter 2026.

This filing indicates that The Coca-Cola Company has made its latest quarterly financial information available to investors. Reviewing the accompanying press release would provide insights into the company’s recent operational performance and financial standing.

• S&P Global Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on April 28, 2026.
• This Form 8-K pertains to Item 2.02, “Results of Operations and Financial Condition,” and Item 7.01, “Regulation FD Disclosure.”
• On April 28, 2026, the company issued an earnings release discussing its results of operations and financial condition for the first quarter ended March 31, 2026.
• The earnings release also includes certain guidance for 2026.
• This earnings release is furnished as Exhibit 99 to the Form 8-K.

The filing of this 8-K indicates that S&P Global Inc. has released its first-quarter earnings results and provided guidance for the full year 2026. The specific financial details and outlook are expected to be found within the attached Exhibit 99, which is the full earnings release. This information typically provides investors with insights into the company’s recent performance and future expectations, which could be relevant for market assessment.

• The Sherwin-Williams Company filed a Form 8-K with the U.S. Securities and Exchange Commission on April 28, 2026.
• This filing pertains to Item 2.02, Results of Operations and Financial Condition.
• On April 28, 2026, the company issued a press release announcing its financial results for the first quarter ended March 31, 2026.
• The full press release is furnished as Exhibit 99.1 to the Form 8-K.

This 8-K filing confirms Sherwin-Williams has officially released its financial report for the first quarter of 2026. Investors are directed to the accompanying press release (Exhibit 99.1) for specific details regarding the company’s performance during this period. This submission marks the formal disclosure of the latest operational and financial condition, which may be crucial for assessing the company’s recent trajectory.

• Ecolab Inc. announced its earnings results for the first quarter ended March 31, 2026.
• The announcement was made on April 28, 2026.
• The company filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) regarding these results.
• A News Release (Exhibit 99.1) and Supplemental Data (Exhibit 99.2) to be used in connection with the conference call are furnished as part of the Form 8-K.
• These exhibits will also be published on Ecolab’s official website at www.ecolab.com.

Ecolab’s announcement of its first-quarter earnings provides investors with the latest information to assess the company’s financial performance. Detailed data, available in the furnished news release and supplemental materials, could be a key resource for monitoring future business developments.

• Gilead Sciences, Inc. announced the completion of its acquisition of Arcellx, Inc. on April 28, 2026.
• This acquisition was executed through a tender offer by Gilead’s wholly-owned subsidiary, Ravens Sub, Inc., pursuant to a Merger Agreement dated February 22, 2026.
• The offer consideration included $115.00 per share in cash (the “Closing Amount”), plus one contractual contingent value right (CVR).
• The CVR provides a right to receive an additional $5.00 per CVR in cash on March 31, 2030.
• This CVR payment is contingent on the cumulative worldwide sales of Arcellx’s anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.

Gilead Sciences’ completion of the Arcellx acquisition appears to be a strategic move to enhance its product pipeline, particularly in the cell therapy domain. The inclusion of a contingent value right linked to future product sales suggests an approach to align the acquisition cost with the commercial success of the acquired asset. This transaction could potentially strengthen Gilead’s competitive position within the evolving biotechnology landscape.

• Visa Inc. issued an earnings release announcing financial results for its fiscal second quarter ended March 31, 2026.
• The detailed financial results are furnished in the earnings release, attached as Exhibit 99.1, dated April 28, 2026.
• The company announced it would host a conference call on April 28, 2026, to discuss its fiscal second quarter financial results.
• Visa’s board of directors declared a quarterly cash dividend of $0.670 per share of Class A common stock.
• This dividend is payable on June 1, 2026, to all holders of record as of May 12, 2026.

This announcement reflects Visa’s routine quarterly financial reporting and its ongoing commitment to shareholder returns through dividends. The declaration of a consistent cash dividend may suggest a stable financial position and robust cash flow, which are often key considerations for investors. The details within the full earnings release will provide further context on the company’s performance for the quarter.

• Booking Holdings Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on April 28, 2026.
• This filing relates to the company’s financial results announcement. (Specific financial results were not detailed in the provided document.)
• The company’s common stock (Ticker: BKNG) is registered on The NASDAQ Global Select Market.
• Numerous series of the company’s Senior Notes, with varying coupon rates and maturity dates (e.g., 4.000% Senior Notes Due 2026, 3.000% Senior Notes Due 2030), are registered on The NASDAQ Stock Market LLC.
• The registrant explicitly states that it is not an emerging growth company.

This 8-K filing indicates that Booking Holdings Inc. has announced its financial results for the period in question. Such filings are typically monitored by investors for key performance indicators like revenue, net income, and gross bookings, which provide a snapshot of the company’s operational and financial health. Detailed financial disclosures within an 8-K can offer insights into a company’s past performance and potentially inform future expectations.

• Mondelez International, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on April 28, 2026.
• The Form 8-K reports the issuance of a press release on April 28, 2026, announcing earnings for the first quarter ended March 31, 2026.
• A copy of the press release is furnished as Exhibit 99.1 to the current report.
• The information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.
• The report was signed by Luca Zaramella, Executive Vice President, Chief Operating Officer and Chief Financial Officer.

This filing indicates that Mondelez International has fulfilled its regulatory requirement to disclose its first-quarter earnings information through a press release. Investors typically refer to such press releases for detailed insights into the company’s financial performance and operational highlights for the reported period. The issuance of this document is a standard step in corporate financial reporting, designed to ensure market transparency.

• Welltower Inc. filed a Form 8-K on April 28, 2026.
• The filing announces the company’s operating results for its first quarter ended March 31, 2026.
• A press release, announcing earnings for the quarter, was issued by Welltower Inc. on April 28, 2026.
• A supplemental information package for the quarter ended March 31, 2026, has also been made available on the company’s website (www.welltower.com).
• These documents are furnished as Exhibits 99.1 (Press Release) and 99.2 (Supplemental Information Package) to the Form 8-K.

Welltower Inc.’s announcement of its Q1 2026 operating results, as indicated by this 8-K filing, provides investors with an official update on the company’s financial performance. The availability of a press release and supplemental information package suggests a comprehensive disclosure for stakeholders to review. This information could be pivotal for assessing the company’s current standing and future outlook within the healthcare real estate sector.